Kristagen
Research OnlyAlso known as: EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Research Statistics
Russian bioregulator with exclusively single-group Khavinson institute research; no independent Western replication and mechanism remains theoretical.
Research Dossier
Overview
What is Kristagen and what does the research say?
Mechanism of Action
The proposed mechanisms of Kristagen are based entirely on Russian bioregulator research. No independent Western validation or controlled human studies exist.
How It Works (Simplified)
Kristagen is claimed to target immune system regulation through thymus-related pathways:
Claimed to bind to thymic tissue and modulate gene expression in thymocytes, supporting T-cell maturation and thymic function.
Proposed to influence the differentiation pathways of immune cells, affecting T-cell and B-cell development and ratios.
Claimed to influence cytokine production and balance, potentially normalizing immune response patterns in aged individuals.
Based on Khavinson’s bioregulator theory that short peptides can restore organ-specific gene expression patterns disrupted by aging.
Scientific Pathways
Thymic Regulation Pathway (Claimed Mechanism)
Kristagen (EDG) → Thymic Tissue Binding → Gene Expression Modulation
↓
Thymocyte Function → T-Cell Maturation SupportImmune Cell Differentiation Pathway (Claimed Mechanism)
Kristagen → Immune Progenitor Cells → Differentiation Signaling
↓
T-Cell/B-Cell Ratio Normalization → Immune BalanceNote: These pathways are proposed based on Russian bioregulator theory. No independent Western research has validated these mechanisms.
Important Limitations
- 100% of research from Russian institutes (St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any claims
- No controlled human clinical trials exist
- Bioregulator peptide theory remains controversial in mainstream immunology
- Pharmacokinetics, optimal dosing, and bioavailability in humans not characterized
- Comparison to validated immunomodulators like Thymosin-alpha-1 shows significant evidence gap
- Safety profile in humans not established through rigorous trials
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial effects on immune cell gene expression may begin. Russian protocols suggest early changes in lymphocyte activity. No human pharmacokinetic data available.
Continued treatment in animal models shows progressive effects on thymic function. Cytokine modulation reported in early treatment phases. Human response timeline is unknown.
Russian studies report observable changes in immune parameters after several weeks of treatment. Lymphocyte subpopulation changes noted in observational studies.
Long-term effects based on Russian observational studies. Cyclical treatment protocols often used (10-20 days on, rest periods). Optimal duration and long-term safety in humans are unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Kristagen product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Kristagen with other peptides. Based on published research and mechanistic considerations.
Thymalin
CompatibleBoth target thymus function - Kristagen as a synthetic tripeptide, Thymalin as a thymic extract. May have overlapping immunomodulatory mechanisms.
Vilon
CompatibleFellow Russian bioregulator peptide targeting immune function. Vilon (Lys-Glu) and Kristagen (Glu-Asp-Gly) have distinct sequences with potentially complementary effects.
Thymosin-Alpha-1
CompatibleBoth immunomodulatory peptides - Ta1 with extensive Western clinical validation, Kristagen with only Russian preclinical data. Different mechanisms of immune support.
Epithalon
CompatibleBoth Khavinson bioregulator peptides - epithalon for telomerase/longevity, Kristagen for immune modulation. No known contraindications.
BPC-157
CompatibleDifferent targets - BPC-157 for tissue healing, Kristagen for immune regulation. No known interactions.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Kristagen
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymogen
Glu-Trp, EW dipeptide, Timogen +2 more
A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin. Approved in Russia for immunomodulation with extensive Russian clinical literature. Represents an attempt to create a standardized, synthetic thymic peptide. Not approved by Western regulatory agencies.